HDAC9 and diffuse large B-cell lymphoma: The combination of HDAC inhibitor HBI8000 and EZH2 inhibitor SHR2554 exhibited dramatic anti-tumor activity in both mutant and wild-type DLBCL, which could provide a potential therapeutic modality for the treatment of DLBCL patients.